$53.83
7.33% today
Nasdaq, Apr 04, 08:18 pm CET
ISIN
US9250501064
Symbol
VRNA
Sector
Industry

Verona Pharma plc Sponsored ADR Target price 2025 - Analyst rating & recommendation

Verona Pharma plc Sponsored ADR Classifications & Recommendation:

Buy
100%

Verona Pharma plc Sponsored ADR Price Target

Target Price $80.33
Price $58.09
Potential
Number of Estimates 9
9 Analysts have issued a price target Verona Pharma plc Sponsored ADR 2026 . The average Verona Pharma plc Sponsored ADR target price is $80.33. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 9 Analysts recommend Verona Pharma plc Sponsored ADR to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Verona Pharma plc Sponsored ADR stock has an average upside potential 2026 of . Most analysts recommend the Verona Pharma plc Sponsored ADR stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 42.30 313.53
641.20%
EBITDA Margin -363.19% 33.54%
109.23%
Net Margin -426.15% 2.96%
100.69%

9 Analysts have issued a sales forecast Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR sales estimate is

$314m
Unlock
. This is
646.50% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$399m 849.76%
Unlock
, the lowest is
$265m 530.95%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $42.3m
2025
$314m 641.20%
Unlock
2026
$606m 93.38%
Unlock
2027
$826m 36.27%
Unlock
2028
$1.1b 34.60%
Unlock
2029
$1.4b 29.22%
Unlock

1 Analyst has issued an EBITDA forecast Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR EBITDA estimate is

$105m
Unlock
. This is
168.34% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$105m 168.34%
Unlock
, the lowest is
$105m 168.34%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-154m 128.79%
2025
$105m 168.45%
Unlock
2026
$453m 330.48%
Unlock
2027
$791m 74.82%
Unlock
2028
$949m 19.93%
Unlock
2029
$992m 4.52%
Unlock

EBITDA Margin

2024 -363.19%
2025
33.54% 109.23%
Unlock
2026
74.67% 122.63%
Unlock
2027
95.79% 28.28%
Unlock
2028
85.35% 10.90%
Unlock
2029
69.03% 19.12%
Unlock

3 Verona Pharma plc Sponsored ADR Analysts have issued a net profit forecast 2025. The average Verona Pharma plc Sponsored ADR net profit estimate is

$9.3m
Unlock
. This is
105.08% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$12.6m 106.90%
Unlock
, the lowest is
$6.8m 103.70%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-180m 208.70%
2025
$9.3m 105.15%
Unlock
2026
$107m 1,047.63%
Unlock
2027
$197m 84.58%
Unlock
2028
$243m 23.51%
Unlock
2029
$328m 35.16%
Unlock

Net Margin

2024 -426.15%
2025
2.96% 100.69%
Unlock
2026
17.57% 493.58%
Unlock
2027
23.79% 35.40%
Unlock
2028
21.83% 8.24%
Unlock
2029
22.84% 4.63%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.13 0.11
208.70% 105.16%
P/E 529.69
EV/Sales 14.80

3 Analysts have issued a Verona Pharma plc Sponsored ADR forecast for earnings per share. The average Verona Pharma plc Sponsored ADR EPS is

$0.11
Unlock
. This is
105.09% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.15 106.94%
Unlock
, the lowest is
$0.08 103.70%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.13 208.70%
2025
$0.11 105.16%
Unlock
2026
$1.26 1,045.45%
Unlock
2027
$2.32 84.13%
Unlock
2028
$2.87 23.71%
Unlock
2029
$3.88 35.19%
Unlock

P/E ratio

Current -26.84 15.00%
2025
529.69 2,073.51%
Unlock
2026
46.16 91.29%
Unlock
2027
25.01 45.82%
Unlock
2028
20.25 19.03%
Unlock
2029
14.98 26.02%
Unlock

Based on analysts' sales estimates for 2025, the Verona Pharma plc Sponsored ADR stock is valued at an EV/Sales of

14.80
Unlock
and an P/S ratio of
15.68
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 110.45
2025
14.80 86.60%
Unlock
2026
7.65 48.29%
Unlock
2027
5.61 26.62%
Unlock
2028
4.17 25.70%
Unlock
2029
3.23 22.61%
Unlock

P/S ratio

Current
2025
15.68 86.60%
Unlock
2026
8.11 48.29%
Unlock
2027
5.95 26.61%
Unlock
2028
4.42 25.71%
Unlock
2029
3.42 22.61%
Unlock

Current Verona Pharma plc Sponsored ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Feb 28 2025
Wells Fargo
Locked
Locked
Locked Feb 28 2025
Canaccord Genuity
Locked
Locked
Locked Feb 12 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 21 2025
Roth MKM
Locked
Locked
Locked Jan 10 2025
Truist Securities
Locked
Locked
Locked Jan 08 2025
Wells Fargo
Locked
Locked
Locked Jan 08 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 28 2025
Locked
Wells Fargo:
Locked
Locked
Feb 28 2025
Locked
Canaccord Genuity:
Locked
Locked
Feb 12 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 21 2025
Locked
Roth MKM:
Locked
Locked
Jan 10 2025
Locked
Truist Securities:
Locked
Locked
Jan 08 2025
Locked
Wells Fargo:
Locked
Locked
Jan 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today